
Opinion|Videos|November 22, 2024
Final Thoughts
The panel discussion concludes with final thoughts on the future landscape of newly diagnosed multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Related to this article

Neither the lipoprotein(a) [Lp(a)]-lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.

Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.

AI tools in pharmacy education risk eroding critical thinking, lab competency, and patient safety if used as substitutes for foundational learning.

The Main Street Pharmacy Access Act would let Medicare pay pharmacists for care they can already legally provide, if pharmacies have the time.

Ali A. Habib, MD, discusses how NIMBLE’s hospitalization findings complement symptom outcomes for investigational cemdisiran and highlights pharmacists’ role in vaccination tracking and infection-risk counseling.

Rather than requiring a new trial, the FDA extended evidence from carcinoma in situ to high-grade papillary-only disease, a new approach for this setting.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Cemdisiran Could Mean for Myasthenia Gravis Treatment and Patient Safety
2
VYD2311 May Offer Vaccine-Hesitant and Immunocompromised Individuals a New COVID-19 Immunization Option
3
Celebrate the Path to MTM During American Pharmacists Month
4
The Future of Health Care Access Runs Through the Pharmacy
5


